Immunome (IMNM)
(Real Time Quote from BATS)
$14.80 USD
+0.14 (0.96%)
Updated Apr 24, 2024 10:22 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
IMNM 14.80 +0.14(0.96%)
Will IMNM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMNM
New Strong Sell Stocks for April 4th
Company News for Apr 2, 2024
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
Here's What Could Help Immunome, Inc. (IMNM) Maintain Its Recent Price Strength
Other News for IMNM
Immunome initiated with bullish view at Guggenheim
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Immunome to presents preclinical data for IM-3050 at AACR